CoChat

A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

This study was a 10-week double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in youth with autism spectrum disorder (ASD). Participants were ages 5 to 17 years with ASD and clinically significant anxiety (Pediatric Anxiety Rating Scale [PARS] score ≥10). Thirty participants were randomized to mirtazapine (7.5-45 mg/day) or placebo in a 2:1 ratio. The co-primary outcome measures were the PARS and the Clinical Global Impressions-Improvement subscale (CGI-I). Mirtazapine resulted in a statistically significant within group decrease in anxiety on the PARS (ES 1.76, p < 0.001). The improvement in PARS score for mirtazapine versus placebo was clinically meaningful but not statistically significant (ES = 0.63, p = 0.64). Forty-seven percent of participants assigned to mirtazapine (95% CI 22%: 74%) and 20% assigned to placebo (95% CI 2%: 60%) were rated "much improved" (CGI-I = 2) or "very much improved" (CGI-I = 1) for anxiety, p = 0.46. No statistically significant differences in mean 10-week changes between mirtazapine and placebo occurred on any outcome measure. There were no statistically significant differences in adverse effect frequency between mirtazapine and placebo. The results are consistent with mirtazapine's safety and tolerability and meet three of four pre-specified indicators of efficacy (statistically significant change in total PARS score for mirtazapine, numerically greater reduction in total PARS score for mirtazapine than placebo, numerically higher number of responders to mirtazapine than placebo, but not greater than 50% of participants receiving mirtazapine rated as responders). Implementation of a larger randomized controlled trial of mirtazapine for the treatment of anxiety in this population is supported.Clinical trial registration information: Mirtazapine Treatment of Anxiety in Children and Adolescents with Pervasive Developmental Disorders; https://clinicaltrials.gov ; NCT01302964.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41386-022-01295-4

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 3

  1. Anxiety Disorders Interview Schedule (ADIS-IV) Child/Parent Version Combination Specimen Set - Wendy K. Silverman; Anne Marie Albano - Oxford University Press. https://global.oup.com/academic/product/anxiety-disorders-interview-schedule-adis-iv-childparent-version-combination-specimen-set-9780195186741?cc=us&lang=en&. Accessed 23 June 2020.
  2. PPVT-4 Peabody Picture Vocabulary Test 4th Edition. https://www.pearsonassessments.com/store/usassessments/en/Store/Professional-Assessments/Academic-Learning/Brief/Peabody-Picture-Vocabulary-Test-%7C-Fourth-Edition/p/100000501.html. Accessed 23 June 2020.
  3. Vineland Adaptive Behavior Scales – Second Edition (VinelandTM-II) - TSLAT. http://www.txautism.net/evaluations/vineland-adaptive-behavior-scales-second-edition-vinelandtm-ii. Accessed 23 June 2020.

Cited by

See all 39

Metadata

Authors
McDougle, C. J., Thom, R. P., Ravichandran, C. T., Palumbo, M. L., Politte, L. C., Mullett, J. E., Keary, C. J., Erickson, C. A., Stigler, K. A., Mathieu-Frasier, L., & Posey, D. J.
Affiliations
  • Harvard University (US)
  • University of North Carolina at Chapel Hill (US)
  • Massachusetts General Hospital (US)
  • Cincinnati Children's Hospital Medical Center (US)
  • Indiana University Indianapolis (US)
Corresponding author
McDougle, Christopher J.
Venue
Neuropsychopharmacology
Published
2022-03-03
Volume
47
Issue
6
Pages
1263-1270
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W4214917350
Cited by
31
References
31
Citations by year
2026: 3 · 2025: 9 · 2024: 8 · 2023: 8 · 2022: 3
FWCI
3.61
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
Funders
Autism Speaks (#5717)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
mirtazapine, autism spectrum disorder, childhood anxiety, children and adolescents, selective serotonin reuptake inhibitors, adverse effects, drug safety and tolerability, treatment efficacy
MeSH terms
Autism Spectrum Disorder, Mirtazapine, Adolescent, Anxiety, Anxiety Disorders, Child, Child, Preschool, Double-Blind Method, Humans, Pilot Projects, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. https://app.cochat.ai/papers/10.1038/s41386-022-01295-4
The paper
McDougle, C. J., Thom, R. P., Ravichandran, C. T., Palumbo, M. L., Politte, L. C., Mullett, J. E., Keary, C. J., Erickson, C. A., Stigler, K. A., Mathieu-Frasier, L., & Posey, D. J. (2022). A randomized double-blind, placebo-controlled pilot trial of mirtazapine for anxiety in children and adolescents with autism spectrum disorder. Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01295-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.